Bristol Myers faces billion-dollar claim over cancer drug

An ICC panel in New York is hearing a US$1.5 billion claim against US pharmaceuticals group Bristol Myers Squibb over the supply of a cancer therapy drug that was blocked by Chinese regulators.

Unlock unlimited access to all Global Arbitration Review content